- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 22, 2023
Deals
March 21 Quick Takes: Yescarta records OS benefit in second-line setting
Plus: Selecta, Sobi’s gout treatment meets in Phase III and updates from Zura, NIH and more
BioCentury | Aug 20, 2021
Product Development
The TAC universe grows beyond PROTACs
Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation
BioCentury | Apr 10, 2020
Product Development
COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Mar 19, 2020
Emerging Company Profile
OncoOne: targeting oxidized MIF for solid tumors
Led by Shire vets, the Austrian biotech is taking aim at a highly selective tumor antigen the biotech left behind
BioCentury | Jul 12, 2019
Company News
MediciNova gets bounce after revealing clinical plan for MS therapy
BioCentury | Apr 19, 2019
Targets & Mechanisms
The next wave in neurodegeneration expands beyond neurons
Why modulating microglia could give drug developers a new handle on neurodegeneration
Items per page:
1 - 10 of 75